LCTX - Lineage Cell Therapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.8087
-0.0276 (-3.30%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8363
Open0.8900
Bid0.8574 x 1400
Ask0.8599 x 1200
Day's Range0.7956 - 0.9000
52 Week Range0.5300 - 1.7300
Volume935,363
Avg. Volume728,537
Market Cap121.138M
Beta (5Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-0.3730
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
  • BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why
    Zacks

    BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why

    BioTime, Inc. (LCTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Business Wire

    Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 2,383,090 shares of common stock of OncoCyte Corporation at a price to buyers of $2.156 per share, representing the average closing price of OncoCyte common stock over the five trading days prior to the execution of the agreement. Net proceeds from the sale were approximately $5 million. The sale is expected to close by January 9, 2020, subject to certain closing conditions. Following the completion of the sale, Lineage will own approximately 6 million shares, which represents less than 10% of OncoCyte’s outstanding common stock. Based on the closing price of OncoCyte’s common stock on January 2, 2020, the value of Lineage’s remaining OncoCyte shares following the closing is approximately $13.5 million. Lineage has agreed not to sell additional shares of OncoCyte common stock until March 17, 2020 or unless the OncoCyte common stock price closes above $3.40.

  • Business Wire

    Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced additional patient data from its ongoing Phase I/IIa clinical study of OpRegen®, the Company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (dry AMD), a leading cause of adult blindness in the developed world with no FDA-approved treatment options.

  • Should You Buy Lineage Cell Therapeutics, Inc. (LCTX)?
    Insider Monkey

    Should You Buy Lineage Cell Therapeutics, Inc. (LCTX)?

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

  • Business Wire

    Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced that it has entered into license agreements with three separate companies, each relating to different parts of Lineage’s intellectual property portfolio. All three companies have ongoing commercial operations, including with respect to their cell therapy-related assets. The aggregate up-front cash payment from the transactions was greater than one million dollars with additional cash and royalties due upon reaching certain development milestones or product sales.

  • Business Wire

    Lineage Cell Therapeutics Provides Shareholder Update

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided a year-end review and an outline of clinical and business plans for 2020.

  • Business Wire

    Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled "Methods of Reprogramming Animal Somatic Cells" covering what is commonly designated "induced Pluripotent Stem (iPS) cells." The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body. The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012.

  • Business Wire

    AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells

    AgeX Therapeutics, Inc. (NYSE American: AGE) and Lineage Cell Therapeutics, Inc. (NYSE American and TASE LCTX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled "Methods of Reprogramming Animal Somatic Cells" covering what is commonly designated "induced Pluripotent Stem (iPS) cells. The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body. The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012.

  • Business Wire

    Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update on OPC1, the Company’s oligodendrocyte progenitor cell (OPC) therapy currently being tested in a Phase I/IIa clinical trial, the SCiStar Study, for the treatment of acute spinal cord injury (SCI). Lineage reported positive results from the ongoing SCiStar study of OPC1, where the overall safety profile of OPC1 has remained excellent with robust motor recovery in upper extremities maintained through Year 2 patient follow-ups available to date.

  • Business Wire

    Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    CARLSBAD, Calif.-- -- New Data from Phase I/IIa Clinical Study of OpRegen ® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last Visit Implemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020 Received CE Mark Approval for Renevia ® ; Working to Identify European Commercial Partner Conducted Sales of 6.25 Million Shares of OncoCyte Corporation ...

  • Business Wire

    Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its third quarter 2019 financial and operating results on Tuesday, November 12, 2019, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, November 12, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2019 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.

  • Business Wire

    Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019

    Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will participate in Solebury Trout’s KOL Event for analysts and investors on November 15, 2019 at 11am ET in New York City at the offices of White & Case, LLP.

  • Business Wire

    Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting

    Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal Investigator and Director of R&D, served as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the Company’s Vision Restoration Program at Neuroscience ...

  • Business Wire

    Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019

    Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L.

  • Business Wire

    Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (dry AMD). The results were presented at the 2019 American Academy of Ophthalmology Annual Meeting (AAO 2019) in San Francisco, CA on October 14th, 2019. Data from the study demonstrate that treatment with OpRegen continues to be well tolerated and, at the furthest time point collected, all four Cohort 4 patients treated to date have better visual acuity on an Early Treatment Diabetic Retinopathy Scale (ETDRS) in the treated eye (range +8 to +19 letters) than in the untreated eye (range -2 to +7 letters).

  • Business Wire

    Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting on October 23, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal Investigator and Director of R&D, will serve as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the Company’s Vision Restoration Program at Neuroscience 2019, the Society for Neuroscience’s 49th Annual Scientific Meeting, to be held at the McCormick Center in Chicago, IL (October 19-23, 2019). The presentation, entitled “Transplantation of human embryonic stem cell derived retinal sheets improves vision in immunodeficient rats with retinal degeneration,” will be presented as part of the Neural Differentiation, Transplantation and Regeneration Session on Wednesday, October 23rd, 2019 at 8:00 am Eastern Time in room S505 (Session #626).

  • Business Wire

    Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019

    Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration , will be presented at the 2019 ...